Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 18 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-0.82 Insider Own2.81% Shs Outstand361.49M Perf Week-9.33%
Market Cap632.61M Forward P/E- EPS next Y-0.56 Insider Trans0.00% Shs Float351.32M Perf Month-1.13%
Income-192.07M PEG- EPS next Q-0.18 Inst Own46.60% Short Float7.16% Perf Quarter-28.28%
Sales2.31M P/S273.86 EPS this Y11.96% Inst Trans11.63% Short Ratio9.01 Perf Half Y37.80%
Book/sh1.17 P/B1.49 EPS next Y18.80% ROA-66.24% Short Interest25.14M Perf Year-27.69%
Cash/sh0.98 P/C1.78 EPS next 5Y- ROE-101.92% 52W Range0.92 - 3.73 Perf YTD14.38%
Dividend Est.- P/FCF- EPS past 5Y6.80% ROI-48.77% 52W High-53.08% Beta1.35
Dividend TTM- Quick Ratio15.56 Sales past 5Y186.21% Gross Margin69.62% 52W Low90.22% ATR (14)0.13
Dividend Ex-Date- Current Ratio15.58 EPS Y/Y TTM-30.42% Oper. Margin-8045.91% RSI (14)47.45 Volatility8.58% 6.86%
Employees285 Debt/Eq0.37 Sales Y/Y TTM1734.13% Profit Margin-8311.12% Recom1.67 Target Price6.20
Option/ShortYes / Yes LT Debt/Eq0.36 EPS Q/Q-16.69% Payout- Rel Volume0.90 Prev Close1.72
Sales Surprise-21.43% EPS Surprise-11.11% Sales Q/Q4608.33% EarningsMay 02 AMC Avg Volume2.79M Price1.75
SMA20-0.37% SMA50-1.01% SMA2004.95% Trades Volume2,516,233 Change1.74%
Date Action Analyst Rating Change Price Target Change
Jun-17-24Initiated H.C. Wainwright Buy $10
Apr-30-24Initiated Leerink Partners Outperform $5
Mar-07-23Initiated Jefferies Hold $3
Aug-12-22Initiated Piper Sandler Overweight $10
Jan-29-21Upgrade JP Morgan Underweight → Neutral $7
Jan-29-21Downgrade Wedbush Outperform → Neutral $2 → $8
Dec-08-20Upgrade Citigroup Neutral → Buy
Nov-18-20Upgrade Gabelli & Co Hold → Buy
Dec-11-19Downgrade Gabelli & Co Buy → Hold
Nov-08-19Downgrade Citigroup Buy → Neutral $3 → $4
Today 08:00AM
Jun-14-24 08:00AM
May-30-24 04:45AM
May-29-24 07:30AM
May-14-24 08:03AM
07:00AM Loading…
May-09-24 07:30AM
May-06-24 10:05AM
May-03-24 07:46AM
May-02-24 08:59PM
10:42AM Loading…
Apr-29-24 10:42AM
Apr-18-24 08:00AM
Apr-16-24 12:00PM
Apr-03-24 08:00AM
Mar-25-24 09:20AM
Mar-13-24 12:45PM
Mar-12-24 08:00AM
Mar-11-24 08:25AM
Feb-29-24 10:00AM
12:58PM Loading…
Feb-22-24 12:58PM
Jan-31-24 05:06AM
Jan-23-24 05:21AM
Jan-08-24 07:00AM
Dec-26-23 05:06AM
Dec-21-23 04:15PM
Nov-30-23 07:30AM
Nov-22-23 07:30AM
Nov-15-23 01:03AM
Nov-12-23 02:10PM
Nov-10-23 04:01PM
Nov-08-23 09:45PM
Nov-03-23 09:00AM
Nov-02-23 09:00AM
Nov-01-23 09:00AM
Oct-31-23 04:01PM
Oct-30-23 04:01PM
Oct-25-23 08:45AM
Oct-17-23 04:01PM
Oct-13-23 11:38AM
Oct-11-23 11:13AM
Oct-10-23 11:25AM
Oct-09-23 04:01PM
Sep-28-23 09:00AM
Sep-26-23 09:00AM
Sep-20-23 12:28PM
Sep-14-23 09:40PM
Sep-07-23 04:30PM
Aug-21-23 09:00AM
Aug-17-23 09:56AM
Aug-08-23 09:00AM
Aug-04-23 09:12AM
Aug-03-23 05:15PM
Jul-28-23 04:01PM
Jun-30-23 06:52AM
Jun-27-23 06:46AM
Jun-23-23 08:45PM
Jun-20-23 08:00AM
Jun-15-23 05:00PM
Jun-06-23 04:01PM
Jun-05-23 04:01PM
Jun-04-23 07:00AM
Jun-02-23 09:21AM
Jun-01-23 11:35AM
May-31-23 04:01PM
May-26-23 04:25PM
May-22-23 07:33AM
May-11-23 06:50AM
May-10-23 04:30PM
May-04-23 10:05AM
May-03-23 11:45AM
May-02-23 04:00PM
Apr-28-23 04:00PM
Apr-22-23 08:15AM
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SOBECKI CHRISTOPHER JDirectorApr 28 '24Option Exercise0.008,0320167,055Apr 29 04:20 PM
Swain Judith LDirectorApr 28 '24Option Exercise0.008,032048,364Apr 29 04:21 PM
DEBBANE RAYMONDDirectorApr 28 '24Option Exercise0.008,03201,348,879Apr 29 04:17 PM
LEFKOWITZ ROBERT J MDDirectorApr 28 '24Option Exercise0.008,032048,364Apr 29 04:18 PM
BARKER SAM LDirectorApr 28 '24Option Exercise0.008,032087,649Apr 29 04:17 PM
Amouyal PhilippeDirectorApr 28 '24Option Exercise0.008,0320248,364Apr 29 04:16 PM
COATS LONNELChief Executive OfficerNov 16 '23Buy1.0590,00094,797914,359Nov 17 04:55 PM
COATS LONNELChief Executive OfficerNov 10 '23Buy1.0110,00010,100824,359Nov 13 05:31 PM
DEBBANE RAYMONDDirectorOct 12 '23Buy1.03148,820153,8051,340,847Oct 12 04:01 PM
DEBBANE RAYMONDDirectorOct 11 '23Buy1.08342,874370,7841,192,027Oct 12 04:01 PM
DEBBANE RAYMONDDirectorOct 10 '23Buy1.14508,306579,367849,153Oct 12 04:01 PM
WADE JEFFREY LPresident and CFOSep 14 '23Buy1.3810,00013,800264,341Sep 14 05:05 PM
McDermott WendyVP, Human ResourcesAug 04 '23Buy1.846,00011,04028,478Aug 07 04:13 PM
COATS LONNELChief Executive OfficerJun 29 '23Buy2.1610,00021,600814,359Jun 29 04:13 PM
COATS LONNELChief Executive OfficerJun 26 '23Buy2.1810,00021,792804,359Jun 26 04:04 PM
COATS LONNELChief Executive OfficerJun 23 '23Buy2.5010,00024,950794,359Jun 26 04:04 PM
McDermott WendyVP, Human ResourcesJun 23 '23Buy2.4310,00024,30022,478Jun 27 04:22 PM
COATS LONNELChief Executive OfficerJun 22 '23Buy2.3140,00092,400784,359Jun 22 04:01 PM
WADE JEFFREY LPresident and CFOJun 20 '23Buy2.3312,00028,000254,341Jun 20 04:10 PM